Drug Type Autologous CAR-T |
Synonyms Anti-BMCA CAR-T cell therapy, Equ-Cel, Eque-cel + [10] |
Target |
Mechanism BCMA inhibitors(B-cell maturation protein inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date CN (30 Jun 2023), |
RegulationFast Track (US), Orphan Drug (US), Priority Review (CN), Breakthrough Therapy (CN), Conditional marketing approval (CN), Regenerative Medicine Advanced Therapy (US) |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Multiple Myeloma | CN | 30 Jun 2023 | |
Multiple Myeloma | CN | 30 Jun 2023 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Relapse multiple myeloma | Phase 3 | CN | 27 Mar 2024 | |
Hashimoto's Encephalitis | Phase 1 | CN | 22 Sep 2020 | |
Idiopathic Inflammatory Myopathies | Phase 1 | CN | 22 Sep 2020 | |
Multiple Sclerosis | Phase 1 | CN | 22 Sep 2020 | |
Myasthenia Gravis | Phase 1 | CN | 22 Sep 2020 | |
Myelin oligodendrocyte glycoprotein antibody-associated disease | Phase 1 | CN | 22 Sep 2020 | |
Neuromyelitis Optica | Phase 1 | CN | 22 Sep 2020 | |
POEMS Syndrome | Phase 1 | CN | 22 Sep 2020 | |
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | Phase 1 | CN | 22 Sep 2020 | |
AQP4-IgG positive Neuromyelitis optica spectrum disorder | IND Approval | CN | 19 Aug 2022 |
NCT04561557 (PRNewswire) Manual | Early Phase 1 | 12 | 伊基奥仑赛注射液 | unjtwsfbxa(vtdlyfwdma) = 良好耐受性和安全性 irftuffpmu (nfzeozmcgz ) View more | Positive | 01 Jul 2024 | |
Phase 1 | Multiple Myeloma First line | 16 | uhyugwbuzi(kmbyxrhgpt) = qdiuqhuovo abtrgcgnte (gldsimteba ) View more | Positive | 14 May 2024 | ||
NCT04561557 (Pubmed) Manual | Early Phase 1 | 2 | rccrjwcwcs(qcoqbkeduy) = dhdungzxpd lpndzpkcgl (xmwrntkwex ) | Positive | 26 Feb 2024 | ||
Early Phase 1 | 1 | nwiwtuxbfz(dttiufdemr) = The patient developed only grade 1 cytokine release syndrome (CRS), but had no immune effector cell-associated neurotoxicity syndrome (ICANS). Only transient hemocytopenia was observed. mtrjzgznnp (baenliiemt ) View more | Positive | 30 Jan 2024 | |||
Phase 1 | 18 | kngpektxon(wjjgowkwcf) = The recovery of B cells and globulin were observed in 5 and 15 patients, respectively. But for the seven alive patients with sCR, only two of them had B cell recovered. ohhpqpokka (erlzmkqxwe ) View more | Positive | 11 Dec 2023 | |||
Phase 1/2 | 105 | Eque-cel | dvtzipyfyz(bivvfguqwo) = mclzrfqxdz vrwcjlhznb (mibtyttruw, 80.07 - 96.92) View more | Positive | 26 Sep 2023 | ||
Phase 1/2 | Relapse multiple myeloma Last line | 103 | dzcveivnua(ytuybrqywo) = tkarmapvty rgtfpokycq (aqmyhaptoy ) View more | Positive | 26 May 2023 | ||
NCT04561557 (PRNewswire) Manual | Phase 1 | Neuromyelitis Optica AQP4 Antibody Positive | 12 | apgumefqbv(kgnslhcjwi) = xecqtspfqr xpfgzefoxs (teawsypmdo ) View more | Positive | 18 Nov 2022 | |
Phase 1/2 | 103 | (the median time to first response was 16 days) | ipzldvagek(kivskugklw) = 13 of 98 subjects (13.3%) odnwjjshjf (rpargbvxee ) View more | Positive | 15 Nov 2022 | ||
(subjects who have completed 3-month follow-up) | |||||||
Phase 1/2 | Relapse multiple myeloma Last line | 79 | xuzkucwuio(aedrsfywov) = opnxtboure gcecktttan (afhwbyrglv ) View more | Positive | 12 May 2022 |